Filter Results :

Your search for Immune returned 112 reports

Sort by


Immune Pharmaceuticals Inc (IMNP) - Medical Equipment - Deals and Alliances Profile

12 Jul 2017  |  Published by:  GlobalData
SummaryImmune Pharmaceuticals Inc (Immune Pharma) formerly EpiCept Corporation, is a pharmaceutical company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer. The company's bertilimumab is under clinical development for moderate to severe ulcerat...

$ 250.00

Read More

AC Immune SA (ACIU) - Medical Equipment - Deals and Alliances Profile

11 Jul 2017  |  Published by:  GlobalData
SummaryAC Immune SA (AC Immune) is a biopharmaceutical company that discovers, designs, and develops products for modifying and preventing diseases caused due to misfolded proteins. The company's pipeline product candidates include anti- abeta antibody, anti-abeta vaccine, anti-ptau vaccine, and tau...

$ 250.00

Read More

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017

01 Jul 2017  |  Published by:  DelveInsight
DelveInsight’s, “Immune Checkpoints Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed...

$ 2,950.00

Read More

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

13 Jun 2017  |  Published by:  GBI Research
SummaryIn 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages...

$ 4,995.00

Read More

Acquired (Autoimmune) Hemolytic Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jun 2017  |  Published by:  DelveInsight
Acquired (Autoimmune) Hemolytic Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Acquired (Autoimmune) Hem...

$ 2,000.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jun 2017  |  Published by:  DelveInsight
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective o...

$ 2,000.00

Read More

Acquired (Autoimmune) Hemolytic Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Jun 2017  |  Published by:  DelveInsight
Summary'Acquired (Autoimmune) Hemolytic Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the unders...

$ 2,000.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Jun 2017  |  Published by:  DelveInsight
Summary'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the re...

$ 2,000.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Insights, 2017

01 Jun 2017  |  Published by:  DelveInsight
DelveInsight’s, “ Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). The DelveInsigh...

$ 1,250.00

Read More

Primary Immune Deficiency (PID)-Pipeline Insights, 2017

01 Jun 2017  |  Published by:  DelveInsight
DelveInsight’s, “ Primary Immune Deficiency (PID)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Primary Immune Deficiency (PID). The DelveInsight’sReport covers the product profiles in various stages of development inclu...

$ 1,250.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura)-Pipeline Insights, 2017

01 Jun 2017  |  Published by:  DelveInsight
DelveInsight’s, “ Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura). The DelveInsight’...

$ 1,250.00

Read More

Immune Check Activators- Competitive Landscape, Technology and Pipeline Analysis, 2016

01 Jun 2017  |  Published by:  DelveInsight
DelveInsight's report deals with the TNFR/TNF superfamily members as agents of Cancer Immunotherapy that have brought a new dawn upon the existing therapies for cancer. Controlling diverse facets of immune function, it has brought into application a technology that rested in the pipeline for years. ...

$ 1,575.00

Read More

Acquired (Autoimmune) Hemolytic Anemia-API Insights, 2017

01 Jun 2017  |  Published by:  DelveInsight
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API ...

$ 1,250.00

Read More

TapImmune Inc (TPIV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

17 May 2017  |  Published by:  GlobalData
SummaryTapImmune Inc (TapImmune) is a clinical-stage immuno-oncology company that develops peptide and gene based immunotherapeutics and vaccines in the areas of cancers and infectious diseases. The company’s pipeline products include TPIV 200, which is intended for the treatment of ovarian and brea...

$ 250.00

Read More

MedImmune LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

17 May 2017  |  Published by:  GlobalData
SummaryMedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibod...

$ 250.00

Read More
Total 112 records.